



Verona Pharma

11 March 2019

PDMR Dealing

LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 8, 2019, Dr. David Ebsworth, Chairman of the Company, purchased a further 17,500 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 57 pence per Ordinary Share and a total purchase price of £9,975.00. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 235,387 Ordinary Shares, representing 0.22% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	David Ebsworth	
2	Reason for the notification		
a)	Position/status	Chairman	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Verona Pharma plc	
b)	LEI	213800EVI606J3TIAL06	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 5 pence each	
	Identification code	GB00BYW2KH80	
b)	Nature of the transaction	David Ebsworth purchased 17,500 Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		57 pence per Ordinary Share	17,500 Ordinary Shares
d)	Aggregated information	N/A	
	<ul style="list-style-type: none"> • Aggregated volume • Price 		
e)	Date of the transaction	8 March 2019	
f)	Place of the transaction	London Stock Exchange, AIM	

For further information, please contact:

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications

info@veronapharma.com

Stifel Nicolaus Europe Limited (Nominated Adviser and
UK Broker)

Tel: +44 (0) 20 7710 7600

Stewart Wallace / Jonathan Senior / Ben Maddison

For further information please contact: Verona Pharma plc

Verona Pharma plc

Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

Stifel Nicolaus Europe Ltd (Nominated Adviser and UK Broker)

Jonathan Senior / Stewart Wallace
Tel: +44 (0)20 7710 7600

FTI Consulting

Simon Conway / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)

James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of

RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.